Overview

Methylphenidate in Myotonic Dystrophy Type 1

Status:
Completed

Trial end date:
2010-09-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine whether methylphenidate is effective in the treatment of excessive daytime sleepiness due to myotonic dystrophy type 1 (DM1).

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Laval University

Treatments:

Methylphenidate